Compare Gilead Sciences, Inc. (GILD) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs TJX Companies Inc — how do they compare? Gilead Sciences, Inc. trades at $135.36 (market cap $163.51B), while TJX Companies Inc trades at $151.21 (market cap $166.78B). The key difference: Gilead Sciences, Inc. and TJX Companies Inc are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | TJX | |
|---|---|---|
Market Cap | $163.51B | $166.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $168.41 |
52-Week Low | $108.22 | $121.35 |
Enterprise Value | $178.05B | $175.38B |
Dividend Yield | 2.49% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
TJX Companies (TJX) trades at $154.81, up 2.97% today, with strong earnings beats in recent quarters. The stock shows a bullish fundamental profile with 9.4% net income margin and 61.25% ROE, though technical indicators signal near-term bearish pressure. Revenue growth accelerated to $56.36B in 2025, with analyst consensus strongly favoring Buy ratings (88.46%). Recent news highlights TJX as a defensive retail play during economic uncertainty, with expansion in international markets like Europe and Australia.
Outlook remains positive given consistent earnings outperformance and robust cash flow, but valuation multiples (P/E 29.37) suggest premium pricing. Key risks include consumer spending volatility and competitive pressures. Wall Street's average price target of $181.80 implies ~17% upside, supported by institutional confidence and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
